The two human monoclonal antibodies (mAbs) against PCSK9 currently available, evolocumab and alirocumab, have a central role in dyslipidemia management, especially after the ambitious LDL-C goals outlined in the last guidelines. This evidence concerns the gene PCSK9 and metabolic syndrome.